solute carrier family 48 member 1Genealiases: HRG-1 · HRG1 · hHRG-1
Q-omics provides the consensus-scored SLC48A1 profile across patient tissues and cancer cell-line models. SLC48A1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SLC48A1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, SLC48A1 RNA expression shows 20,476 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, KIRC, and GBM as cancer lineages where SLC48A1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC48A1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC48A1 survival associations across molecular data types. SLC48A1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC48A1 RNA expression–survival associations across cancer types. High SLC48A1 expression shows unfavorable associations in LIHC, but favorable associations in MESO, CESC, ACC, KICH and BRCA. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify MESO as the clearest survival context for SLC48A1 RNA expression.
This table summarizes SLC48A1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for SLC48A1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC48A1 shows lower tumor expression in KIRC, KICH, LUAD and BLCA and higher tumor expression in LIHC and COAD. The KIRC box plot shows higher SLC48A1 RNA expression in normal versus tumor tissue (log2 FC = −1.787, t-test p < 0.001).
This table shows molecular features associated with SLC48A1 in patient tissues and cancer cell lines. In patient samples, SLC48A1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC48A1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in STOMACH, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
